Subscribe to RSS
DOI: 10.1055/s-0033-1337964
Prediction of Outcome by Early Response in Childhood Acute Lymphoblastic Leukemia
Das frühe Ansprechen auf die Therapie als prognostischer Faktor bei der akuten lymphoblastischen Leukämie im KindesalterPublication History
Publication Date:
22 May 2013 (online)
![](https://www.thieme-connect.de/media/klinpaed/2013S01/lookinside/thumbnails/10.1055-s-0033-1337964-1.jpg)
Abstract
Background:
In the ALL-BFM studies for treatment of acute lymphoblastic leukemia, reduction of leukemic blasts in peripheral blood after a one-week prednisone pre-phase – the so-called prednisone response – has been used for risk stratification since the 1980s and has been one of the most relevant factors for identification of high-risk patients. In the trial ALL-BFM 95, early cytomorphological marrow response on day 15 of induction therapy was prospectively evaluated and its prognostic value was analyzed in comparison to the prednisone response and other established prognostic factors.
Results:
Compared to prednisone response, day 15 marrow response was superior in outcome prediction – yet with differential effect depending on blast lineage. Outcome was poor in T cell leukemia patients with prednisone poor-response independent of day 15 marrow response, whereas among patients with prednisone good-response different risk groups could be identified by day 15 marrow response. In contrast, prednisone response lost prognostic significance in precursor B cell leukemia when stratified by day 15 marrow response.
Conclusions:
Selective addition of day 15 marrow response to conventional stratification criteria applied on ALL-BFM 95 may significantly improve risk-adapted treatment delivery. Even though cutting-edge trial risk stratification is meanwhile dominated by minimal residual disease evaluation, an improved conventional risk assessment, as presented here, could be of great importance to countries lacking the technical and/or financial resources associated with the application of minimal residual disease analysis.
Zusammenfassung
Hintergrund:
Die Blastenreduktion im peripheren Blut nach einer einwöchigen Prednison-Vorphase – der sogenannte Prednison-Response – wird in den ALL-BFM-Studien zur Behandlung von Kindern mit akuter lymphoblastischer Leukämie seit den 1980er Jahren für die Risikostratifizierung herangezogen und stellt einen der wichtigsten Faktoren für die Identifizierung von Hochrisikopatienten dar. In der Studie ALL-BFM 95 wurde zusätzlich das frühe zytomorphologische Ansprechen auf die Therapie am Tag 15 der Induktionstherapie im Knochenmark prospektiv untersucht und dessen prognostischer Wert im Vergleich zum Prednison-Response und anderen etablierten Prognosefaktoren analysiert.
Ergebnisse:
Das zytomorphologische Ansprechen im Knochenmark am Tag 15 war als prognostischer Faktor dem Prednison-Response insgesamt überlegen, jedoch mit unterschiedlichem Effekt in Abhängigkeit vom Immunphänotyp der Blasten. Während bei Patienten mit B-Vorläuferzell-Leukämie der Prednison-Reponse in Kombination mit dem Ansprechen am Tag 15 seine prognostische Wertigkeit komplett verlor, war bei Patienten mit T-Zell-Leukämie ein schlechter Prednison-Response auch bei gutem Ansprechen am Tag 15 prognostisch ungünstig.
Schlussfolgerung:
Die Verwendung des zytomorphologischen Therapieansprechens am Tag 15 in der Induktionstherapie für die Risikostratifizierung kann im Vergleich zur konventionellen Stratifizierung der Studie ALL-BFM 95 eine bessere Risikoadaptierung der Therapie ermöglichen. Auch wenn mittlerweile in vielen aktuellen Therapiestudien die zytomorphologische Evaluation des Therapieansprechens weitgehend durch Methoden zur Erfassung der minimalen Resterkrankung abgelöst wurde, kann insbesondere in Ländern, in denen keine ausreichenden Mittel für Analysen der minimalen Resterkrankung verfügbar sind, eine verbesserte konventionelle Risikoeinschätzung entscheidend zur Qualität der Therapie beitragen.
-
References
- 1 Arico M, Basso G, Mandelli F et al. Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Cancer 1995; 75: 1684-1693
- 2 Bowman WP, Larsen EL, Devidas M et al. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children’s Oncology Group trial P9906. Pediatr Blood Cancer 2011; 57: 569-577
- 3 Chessells JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia. Lancet 1995; 345: 143-148
- 4 Conter V, Bartram CR, Valsecchi MG et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115: 3206-3214
- 5 Dordelmann M, Reiter A, Borkhardt A et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999; 94: 1209-1217
- 6 Felice MS, Zubizarreta PA, Alfaro EM et al. Childhood acute lymphoblastic leukemia: prognostic value of initial peripheral blast count in good responders to prednisone. J Pediatr Hematol Oncol 2001; 23: 411-415
- 7 Fronkova E, Mejstrikova E, Avigad S et al. Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?. Leukemia 2008; 22: 989-997
- 8 Gajjar A, Ribeiro R, Hancock ML et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 1995; 86: 1292-1295
- 9 Gaynon PS. Prognostic factors in acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2000; 22: 403-404
- 10 Gaynon PS, Angiolillo AL, Carroll WL et al. Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: a Children’s Oncology Group Report. Leukemia 2010; 24: 285-297
- 11 Gaynon PS, Bleyer WA, Steinherz PG et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 1990; 18: 273-279
- 12 Gaynon PS, Desai AA, Bostrom BC et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer 1997; 80: 1717-1726
- 13 Gaynon PS, Trigg ME, Heerema NA et al. Children’s Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000; 14: 2223-2233
- 14 Haw R, Sawka CA, Franssen E et al. Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin’s lymphoma: a literature review. J Clin Oncol 1994; 12: 1074-1084
- 15 Keating MJ, Smith TL, Gehan EA et al. Factors related to length of complete remission in adult acute leukemia. Cancer 1980; 45: 2017-2029
- 16 Lange BJ, Bostrom BC, Cherlow JM et al. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood 2002; 99: 825-833
- 17 Lauten M, Moricke A, Beier R et al. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. Haematologica 2012; 97: 1048-1056
- 18 Lauten M, Stanulla M, Zimmermann M et al. Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter. Klin Padiatr 2001; 213: 169-174
- 19 Matloub Y, Bostrom BC, Hunger SP et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood 2011; 118: 243-251
- 20 Matloub Y, Lindemulder S, Gaynon PS et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children’s Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children’s Oncology Group. Blood 2006; 108: 1165-1173
- 21 Miller DR, Leikin S, Albo V et al. Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141. A report from childrens cancer study group. Cancer 1983; 51: 1041-1049
- 22 Miller DR, Leikin S, Albo V et al. Use of prognostic factors in improving the design and efficiency of clinical trials in childhood leukemia: Children’s Cancer Study Group Report. Cancer Treat Rep 1980; 64: 381-392
- 23 Möricke A, Reiter A, Zimmermann M et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008; 111: 4477-4489
- 24 Möricke A, Zimmermann M, Reiter A et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010; 24: 265-284
- 25 Nachman J, Sather HN, Gaynon PS et al. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children’s Cancer Group. J Clin Oncol 1997; 15: 2222-2230
- 26 Oudot C, Auclerc MF, Levy V et al. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study. J Clin Oncol 2008; 26: 1496-1503
- 27 Reiter A, Schrappe M, Ludwig WD et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122-3133
- 28 Riehm H, Reiter A, Schrappe M et al. Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klin Padiatr 1987; 199: 151-160
- 29 Sandlund JT, Harrison PL, Rivera G et al. Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. Blood 2002; 100: 43-47
- 30 Schrappe M, Reiter A, Riehm H. Cytoreduction and prognosis in childhood acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 2403-2406
- 31 Schrappe M, Valsecchi MG, Bartram CR et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 2011; 118: 2077-2084
- 32 Schultz KR, Pullen DJ, Sather HN et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG). Blood 2007; 109: 926-935
- 33 Seibel NL, Steinherz PG, Sather HN et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood 2008; 111: 2548-2555
- 34 Smith M, Arthur D, Camitta B et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 18-24
- 35 Smith M, Bleyer A, Crist W et al. Uniform criteria for childhood acute lymphoblastic leukemia risk classification. J Clin Oncol 1996; 14: 680-681
- 36 Steinherz PG, Gaynon PS, Breneman JC et al. Cytoreduction and prognosis in acute lymphoblastic leukemia – the importance of early marrow response: report from the Childrens Cancer Group. J Clin Oncol 1996; 14: 389-398
- 37 Thyss A, Suciu S, Bertrand Y et al. Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukaemia. The European Organization for Research and Treatment of Cancer Children’s Leukemia Cooperative Group. J Clin Oncol 1997; 15: 1824-1830
- 38 Vora A, Mitchell CD, Lennard L et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 2006; 368: 1339-1348